KBC Group NV raised its position in shares of Mednax, Inc (NYSE:MD) by 258.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,006 shares of the company’s stock after buying an additional 34,624 shares during the period. KBC Group NV owned 0.05% of Mednax worth $2,898,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the stock. State of Alaska Department of Revenue increased its position in shares of Mednax by 5.2% in the first quarter. State of Alaska Department of Revenue now owns 4,136 shares of the company’s stock worth $286,000 after buying an additional 204 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Mednax by 55.2% in the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock worth $5,524,000 after buying an additional 28,301 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Mednax by 7.9% in the first quarter. Prudential Financial Inc. now owns 58,520 shares of the company’s stock worth $4,060,000 after buying an additional 4,270 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Mednax by 527.2% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock worth $919,000 after buying an additional 12,800 shares during the last quarter. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of Mednax during the first quarter worth $357,000.
Shares of Mednax, Inc (MD) opened at 44.22 on Friday. The stock has a 50 day moving average of $49.58 and a 200-day moving average of $59.60. The company has a market cap of $4.08 billion, a PE ratio of 14.08 and a beta of 0.40. Mednax, Inc has a 12 month low of $41.52 and a 12 month high of $72.13.
Mednax (NYSE:MD) last issued its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company had revenue of $843 million during the quarter, compared to analyst estimates of $849.49 million. During the same period in the prior year, the business posted $1.03 EPS. The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. Equities analysts forecast that Mednax, Inc will post $3.31 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Mednax, Inc (MD) Shares Bought by KBC Group NV” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/27/mednax-inc-md-shares-bought-by-kbc-group-nv.html.
A number of equities analysts have commented on MD shares. BidaskClub cut shares of Mednax from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Jefferies Group LLC set a $46.00 price objective on shares of Mednax and gave the stock a “hold” rating in a research report on Sunday, July 30th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th. Mizuho reaffirmed a “neutral” rating and set a $48.00 price objective (down from $62.00) on shares of Mednax in a research report on Tuesday, August 1st. Finally, ValuEngine cut shares of Mednax from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $63.00.
In related news, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total transaction of $113,355.33. Following the sale, the director now directly owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The disclosure for this sale can be found here. 2.40% of the stock is owned by corporate insiders.
About Mednax
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.
